Dr Rajesh Rajan

Today marks the 15th anniversary of my father's passing. Not a day goes by that I don't think about him and miss him deeply. Let's remember him for the incredible person he was and the impact he had on our lives. Forever in my heart.

Someone has created a fake ID ‼️again and is contacting my Facebook friends 🙏. Please help me report this profile and block it.‼️
ആരോ വീണ്ടും ഒരു വ്യാജ ഐഡി ഉണ്ടാക്കി ‼️എൻ്റെ ഫേസ്ബുക്ക് സുഹൃത്തുക്കളെ ബന്ധപ്പെടുന്നു. ഈ പ്രൊഫൈൽ റിപ്പോർട്ട് ചെയ്യാനും ഇത് ബ്ലോക്ക് ചെയ്യാനും എന്നെ സഹായിക്കൂ.‼️

My article in today's 🌍🤝 Supporting , the stands in solidarity and sends its support and love.❤️

Last month, I had the privilege of attending the World Heart Summit in Geneva, Switzerland . As Chairman of the Board of Governors , I was honored to collaborate with global experts on cardiovascular health, organized by & .

World 'NO' To***co Day 2023!
Quitting smoking benefits your cardiovascular health ***coDay "
🪢http://www.arabtimesonline.com/news/quitting-smoking-has-quick-long-term-benefits-for-cardiovascular-health/

in
Several clinical trials have demonstrated the efficacy of Ticagrelor in the treatment of acute coronary syndrome ( ), leading to its inclusion in treatment guidelines. Here are some of the key trials:

1. trial: The PLATO trial was a large, randomized, double-blind trial that compared Ticagrelor to Clopidogrel in patients with ACS. The study involved over 18,000 patients and found that Ticagrelor reduced the risk of cardiovascular death, myocardial infarction, and stroke compared to Clopidogrel. The results of this trial led to Ticagrelor's approval by the FDA in 2011.

2. -TIMI 54 trial: This trial investigated the efficacy of Ticagrelor in patients who had previously experienced a myocardial infarction. The study involved over 21,000 patients and found that Ticagrelor reduced the risk of cardiovascular death, myocardial infarction, and stroke compared to placebo. The results of this trial led to Ticagrelor's inclusion in treatment guidelines for secondary prevention of ACS.

3. THEMIS trial: The trial investigated the efficacy of Ticagrelor in patients with diabetes and stable coronary artery disease. The study involved over 19,000 patients and found that Ticagrelor reduced the risk of cardiovascular death, myocardial infarction, and stroke compared to placebo. The results of this trial led to Ticagrelor's inclusion in treatment guidelines for patients with diabetes and stable coronary artery disease.

Overall, these trials have demonstrated the efficacy of Ticagrelor in reducing the risk of cardiovascular events in patients with ACS and have led to its inclusion in treatment guidelines for ACS and secondary prevention.

"India's new Parliament House is not just the largest, but also unique in its design and technology. A proud moment for the world's largest democracy as we move towards a more modern and efficient system of governance. "

The use of in acute coronary syndrome ( ) is based on several clinical trials, including:

1. ISIS-2 (Second International Study of Infarct Survival): This trial was conducted in the late 1980s and demonstrated that aspirin, when given to patients with suspected myocardial infarction (heart attack), reduced the risk of death by 23%.

2. GUSTO (Global Utilization of Streptokinase and TPA for Occluded Arteries): This trial was conducted in the early 1990s and showed that aspirin, when given to patients with ACS who were undergoing thrombolytic therapy, reduced the risk of death by 25%.

3. CAPRIE (Clopidogrel versus in Patients at Risk of Ischemic Events): This trial was conducted in the late 1990s and compared the efficacy of aspirin and clopidogrel in reducing the risk of cardiovascular events in patients with a history of ACS, stroke, or peripheral vascular disease. The trial showed that clopidogrel was more effective than aspirin in reducing the risk of stroke, but there was no significant difference in the risk of ACS between the two drugs.

4. CURRENT-OASIS 7 (Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organization to Assess Strategies in Ischemic Syndromes): This trial was conducted in the late 2000s and compared the efficacy of high-dose aspirin (300-325 mg/day) versus low-dose aspirin (75-100 mg/day) in combination with clopidogrel in reducing the risk of cardiovascular events in patients with ACS. The trial showed that high-dose aspirin was not superior to low-dose aspirin in reducing the risk of cardiovascular events.

Based on the results of these trials, aspirin is currently recommended as a standard therapy for patients with ACS.

Several studies have shown the benefits of beta-blockers in the management of acute coronary syndrome (ACS). The most widely cited studies are:

1. COMMIT trial: This trial involved over 45,000 patients with acute myocardial infarction and showed that early use of metoprolol reduced mortality and incidence of reinfarction. It reduced the risk of death by 11% and the risk of recurrent myocardial infarction (MI) by 14%.

2. TIMI-IIIB trial: This trial involved over 1,400 patients with unstable angina and showed that the use of propranolol reduced the incidence of myocardial infarction. This study involved patients with unstable angina or non-Q-wave MI and found that the use of beta-blockers reduced the risk of recurrent MI by 36%.

3. CAPRICORN trial: This trial involved over 2,500 patients with left ventricular dysfunction and showed that carvedilol reduced all-cause mortality and hospitalization for heart failure. The study showed that the use of beta-blockers reduced the risk of death by 23% and the risk of hospitalization for heart failure by 40%.

Prime Minister PMO India Shri. Narendra Modi ji 🙏😍

This is a tragic and senseless act of violence against a dedicated medical professional. Our hearts go out to Dr Vandana Das's family and colleagues. It's important to recognize and address the dangers that medical professionals face in their line of work and take measures to ensure their safety.

Good news! My article received enough downloads to be a in its journal.

Kidney disease is one of the most common complications of diabetes and can increase your risk for heart disease. An albumin level at 30 or above may mean you have kidney damage. Talk to your doctor about a uACR test at your next appointment.

📍Under Right to education can govt force all pvt school to teach in free
📍Right to food - ask restaurants to give free food
📍Right to live - free hotel stay
📍Right to travel -free travel
🔜Do all this and we will accept this so called Right to health bill 🏨

in 10:15pm. Just now

Its like a dream come true moment ‼️My research got published in Journal of American College of Cardiology.
📌https://www.sciencedirect.com/science/article/abs/pii/S0735109723010021
📌 https://www.sciencedirect.com/science/article/abs/pii/S0735109723023987

Please 🙏 do visit the poster area on 4th March 2023 ‼️

Showcasing one’s research at American College of Cardiology is an ambition for majority of the cardiologists across the world. Luckly TWO of our abstracts got accepted this time in ACC 23.

𝖂𝖎𝖘𝖍 𝖞𝖔𝖚 𝖆𝖓𝖉 𝖋𝖆𝖒𝖎𝖑𝖞 𝖆 𝖛𝖊𝖗𝖞 𝕳𝖆𝖕𝖕𝖞 𝕹𝖊𝖜 𝖄𝖊𝖆𝖗

Merry Christmas 🎄

Happy Diwali 🪔

Honoured to be the eminent panelist of 2022 ❗️

World Heart Day

It was a nice gesture by Indian Doctors Forum (IDF) Kuwait. First time attending a meeting of IDF ❗️